SCbio’s Life Sciences Accelerator, SCbioDrive, Announces Spring 2025 Cohort of Oncology and Neuroscience Startups

Six emerging life science startups from South Carolina to Ireland to receive guidance, mentoring and business-focused curriculum modules taught by industry experts,  including Deloitte, Eli Lilly, Inspire Agency, Maynard Nexsen, Medpoint and VentureSouth.

SOUTH CAROLINA – April 10, 2025 – SCbio, in partnership with The Massachusetts Biotechnology Council (MassBio), has selected six emerging life sciences companies to participate in the Spring 2025 SCbioDrive Accelerator cohort.

“We are excited to introduce the next cohort for the SCbioDrive Accelerator Program, featuring life sciences startups from across the globe, including Ireland, Canada, Massachusetts, North Carolina and South Carolina,” said SCbio President and CEO James Chappell. “Supporting these emerging companies is key to driving innovation, creating jobs and fostering economic growth here in South Carolina. Most importantly, these companies have the potential to transform patient care and improve lives through their groundbreaking products and services. We look forward to seeing the advancements these startups will achieve in the months ahead.”

An annual program, SCbioDrive will lead six seed-stage life sciences companies through an eight-week hybrid program designed to advance their platforms and technologies through expert business curricula, industry guidance and mentorship – all at no cost.

“I am always impressed with the latest science and technologies being explored in early-stage life sciences startups, and this SCbioDrive cohort is no different,” said MassBio CEO & President Kendalle Burlin O’Connell. “In times of uncertainty, it is even more important to empower founders with the tools and resources they need to be successful in hitting milestones and advancing their innovations closer to patients.”

These startups will participate in business-focused curriculum modules taught by experts,  including Deloitte, Eli Lilly, Inspire Agency, Maynard Nexsen, Medpoint and VentureSouth.

The program will end in June with a Demo Day in Charleston, S.C., where cohort companies will present to a curated group of potential investors and industry leaders.

SCbioDrive Spring 2025 Cohort

  • Genicity (Galway, Ireland) is an innovative cell therapy company pioneering a new frontier in T-cell immunotherapy for incurable diseases and providing treatment solutions to improve outcomes for cancer patients with the highest unmet medical needs. The company is on track to deliver early clinical research data in small-cell lung cancer to the University of Galway within two years, marking a significant milestone in developing next-generation cancer immunotherapies. The team also collaborates with leading cancer centers across Europe, the United States and Japan to advance clinical translation.
  • Lipo-Immuno Tech, LLC (Mount Pleasant, S.C.) was founded to advance anti-cancer strategies that also show promise in treating neurodegenerative disorders like Alzheimer’s disease. Strong mechanistic data support the methods and have the potential to significantly improve patient health. The company specializes in innovative anti-cancer approaches that utilize lipid metabolism/signaling and immunotherapy. Lipo-Immuno Tech offers a unique, two-pronged therapeutic approach with specialized expertise and leadership by targeting lipid metabolism/signaling and boosting the body’s natural anti-cancer immune responses.
  • OsteoCure Therapeutics, Inc. (Durham, N.C.) is a company that originated from Duke University and operates as a global life sciences network for innovation, focused on developing advanced therapies to address critical unmet bone health and regeneration needs. Leveraging cutting-edge research, the company specializes in novel combination products designed to accelerate bone healing, mitigate pain, improve patient outcomes and reduce recovery times for those suffering from orthopedic injuries and conditions. Operating within the rapidly evolving biotechnology and regenerative medicine industries, OsteoCure Therapeutics capitalizes on advancements in small molecule and drug delivery technologies to pioneer new treatment modalities.
  • Sebastian Biopharma (Beverly, M.A.) is a preclinical-stage biotechnology company driven by a singular mission: to develop groundbreaking biologics that offer new therapeutic options for millions of cancer patients. The company utilizes compelling proof-of-concept data from multiple innovative therapeutic strategies and a versatile ‘plug-and-play’ antibody-oligonucleotide conjugate platform to enhance the efficacy of immune checkpoint blockade therapies for cancer treatment. Its lead product – iTAP – is advancing through the lead compound nomination stage.
  • SiNON Nano Sciences (Durham, N.C.) is a biotechnology company pioneering carbon-based nanotechnology for targeted drug delivery, primarily focusing on central nervous system diseases. The company’s patented carbon nanoparticle platform is designed to efficiently cross the blood-brain barrier, enabling safer, more precise and highly effective treatment delivery for neurological disorders, oncology and other hard-to-treat conditions. Operating at the intersection of nanomedicine, drug delivery and precision therapeutics, SiNON is addressing critical challenges in the pharmaceutical industry by enhancing drug solubility, extending circulation time and improving targeted release at disease sites.
  • TATUM bioscience (Sherbrooke, Canada) is dedicated to solving a significant unmet medical need in cancer treatment. Immuno-oncology and the advent of checkpoint inhibitors profoundly revolutionized cancer care by making cancer-free outcomes a reality. However, only 20% of patients respond to these blockbuster immunotherapies, leaving 80% without effective therapeutic solutions. TATUM bioscience is addressing this gap with its innovative approach, nanofilament vaccine immunotherapy. The nanofilaments represent a first-in-class modality that unveils cancer cells and activates the immune system to trigger robust, long-lasting antitumor vaccine responses, offering unmatched response rates and therapeutic efficacy.

To learn more about the SCbioDrive Accelerator Program, visit scbio.org/scbiodrive.

About SCbio

SCbio is the definitive, unifying leader in South Carolina’s life sciences sector, fostering authentic collaboration and innovation across academia, startups, government and established enterprises. As a member-driven economic development organization, SCbio represents more than 1,000 organizations employing more than 87,000 professionals. Our members are unified by a mission to positively impact humanity through science across the ecosystem of advanced and specialty manufacturing; digital health and the data frontier; and cutting-edge health specializations. For additional information about SCbio and the life sciences industry or to become a member, visit www.SCbio.org.

Join now to enjoy expanded member benefits!

Enjoy exclusive member content, special events, savings, networking and more

Paige Durham

SCbio is pleased to welcome Paige Durham to the team as communications coordinator to creatively and effectively communicate the value of the life science association’s programs and initiatives.

Durham will be responsible for developing and distributing high-quality content across multiple communications channels to build, advance and grow South Carolina’s life sciences industry, a key business sector for economic prosperity for the Palmetto State.

“SCbio is excited to welcome Paige to our team as our new communications coordinator. Paige brings fresh ideas and a strong background in communications that will be invaluable as we continue to strengthen our engagement with our audience,” said SCbio President and CEO James Chappell. “We are confident that her skills and experience will be crucial in advancing our communication strategies and supporting our mission.”

Before joining SCbio, Durham was the Membership and Communications Manager at the South Carolina Pharmacy Association (SCPhA), where she used her photography, design and writing skills to create content tailored to pharmacy professionals. Durham’s effective communication skills guaranteed the delivery of brand-specific material that captured the eye of her audience.

During her time at SCPhA, Durham created and edited the Palmetto Pharmacist Journal, using her creative vision to showcase members, educational institutions and industry news. Her communications efforts successfully gained new followers for the organization over the course of a year, increasing brand visibility and promoting the pharmacy profession.

Durham holds a Bachelor of Science in hospitality and tourism management and a Bachelor of Science in business administration from the College of Charleston.

Tamia Sumpter

Tamia is a driven senior undergraduate Bioengineering student currently enrolled at Clemson University. With a strong foundation in her field, she has honed her skills through hands-on experience in research and development at Eli Lilly & Company. During her time in the ADME department, Tamia contributed significantly by working on siRNAs and their applications in finding In Vitro-In Vivo Correlation (IVIVC). Looking ahead, Tamia has set her sights on a promising career in law. She aspires to specialize in Intellectual Property Law, with a particular focus on serving as in-house counsel for leading medical device or pharmaceutical companies. Her enthusiasm for this role is palpable as she prepares to embark on her legal journey! She is also a proud member of the Omicron Phi chapter of Delta Sigma Theta Sorority, Inc., PEER Mentor for Clemson PEER/WiSE, and currently serves as the President of Clemson Bioengineering Organization (CBO). With her unique blend of scientific knowledge and legal interests, Tamia is poised to make a meaningful impact in the healthcare and life sciences industries.